ClinicalTrials.gg
CompletedNCT00558025Updated May 16, 2014Results posted

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

A Phase 3 interventional study of Pramipexole Extended Release and Pramipexole Immediate Release in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 36 sites in 3 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-05-16.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
17th of 26
156 · median 224
Started
2007
with 4 others
Phase 3
11 of 26
none open now
Registered
11th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 17th largest by enrollment, is one of 5 that started in 2007, is one of 11 in phase 3, and was the 11th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The objectives of this trial conducted in early Parkinson's disease (PD) patients are:

  • To assess if patients with early Parkinson's disease (PD) can be successfully switched (overnight switching) from Pramipexole (PPX) Immediate Release (IR) to Pramipexole Extended Release (ER). A successful switch at a specific visit is defined as no worsening of the Unified Parkinsons Disease Rating Scale (UPDRS) parts II+III score by more than 15% from baseline and no drug-related adverse events leading to withdrawal;
  • To establish if this successful switch can be obtained with or without dose-adaptation;
  • To provide information about the conversion ratio (mg:mg) from Pramipexole IR to Pramipexole ER.
03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient with idiopathic Parkinson's disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.
  2. Parkinson's disease diagnosed within 5 years.
  3. Patients 30 years of age or older at the time of diagnosis.
  4. Modified Hoehn and Yahr stage of 1 to 3.
  5. Patients receiving pramipexole IR for at least three months prior to baseline visit (randomization visit, V2).
  6. Pramipexole dose should be optimized (according investigator¿s judgement), greater or equal to 1.5 mg/day, stable and equally divided 3 times per day, for a least 4 weeks prior to baseline visit (V2).
  7. Patients willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
  8. Signed obtained before any study procedures are carried out in accordance with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines and local legislation).

Exclusion criteria

Exclusion Criteria:

  1. Motor complications under levodopa therapy at V1.
  2. Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.
  3. Dementia, as defined by a score \< 24 at V1
  4. Any psychiatric disorder according to , 4th edition (DSM-IV) criteria
  5. History of psychosis, except history of drug induced hallucinations
  6. (ECG) abnormalities at V1.
  7. Clinically significant hypotension either at screening visit or at baseline visit.
  8. Malignant melanoma or history of previously treated malignant melanoma.
  9. Any other clinically significant disease
  10. Pregnancy or breast-feeding.
  11. Sexually active female of
  12. Serum levels of (Serum Glutamic Oxaloacetic Transaminase) (AST (SGOT)), Alanine Aminotransferase (Serum Glutamate Pyruvate Transaminase) (ALT (SGPT)), alkaline phosphatases or > 2 (ULN) (on screening lab test).
  13. Patients with a \< 50 mL/min
  14. Any dopamine agonist (except pramipexole IR) within three months prior to baseline visit.
  15. History of discontinuation of treatment with pramipexole IR
  16. Previous treatment with pramipexole ER.
  17. Any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit (i.e. typical neuroleptics, atypical antipsychotics, reserpine, methyldopa, centrally-active antiemetics, etc).
  18. Any of the following drugs within 4 weeks prior to the baseline visit: methylphenidate, cinnarizine, amphetamines.
  19. Flunarizine within 3 months prior to baseline visit.
  20. Known to Pramipexole or its .
  21. Drug abuse (including alcohol), according to Investigator¿s judgement, within 2 years prior to screening.
  22. Participation in other drug studies or use of other investigational drugs within 4 weeks or five times the half-life of the investigational drug (whichever is longer) prior to baseline visit.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Pramipexole Extended Release (ER)

    Pramipexole Extended Release (ER) once daily

    Drug: Pramipexole Extended Release

  • Experimental
    Pramipexole Immediate Release (IR)

    Pramipexole Immediate Release (IR) once daily

    Drug: Pramipexole Immediate Release

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Who Successfully Switched From Pramipexole Immediate Release (IR) to Pramipexole ER After a Possible Dose Adaptation, Full Analysis Set (FAS), Last Observation Carried Forward (LOCF)

    A successful switch was defined by no change of the Unified Parkinson's Disease Rating Scale (UPDRS) II+III by more than 15% from baseline to week 9, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment)

    Time frame: from baseline to week 9

Secondary outcomes

  1. Percentage of Patients Who Successfully Switched From Pramipexole IR to Pramipexole ER With no Dose Adaptation, FAS (LOCF)

    A successful switch was defined by no change of the UPDRS II+III by more than 15% from baseline to week 4, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment).

    Time frame: from baseline to week 4

  2. Change From Baseline in UPDRS Part II+III Total Score at Week 9, FAS (LOCF)

    Unified Parkinson's Disease Rating Scale part II+III total score on FAS, Week 9 - baseline, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment)

    Time frame: Baseline and week 9

  3. Change From Baseline in UPDRS Part II Total Score at Week 9, FAS (LOCF)

    Unified Parkinson's Disease Rating Scale part II total score on FAS, Week 9 - baseline, UPDRS II score ranging from 0 (no impairment) to 52 (worst impairment)

    Time frame: Baseline and week 9

  4. Change From Baseline in UPDRS Part III Total Score at Week 9, FAS (LOCF)

    Unified Parkinson's Disease Rating Scale part III total score on FAS, week 9 - baseline, UPDRS II+III score ranging from 0 (no impairment) to 108 (worst impairment)

    Time frame: Baseline and week 9

  5. Clinical Global Impression - Improvement (CGI-I), FAS (LOCF)

    Clinical Global Impression - Improvement on FAS, CGI-I was rated from 1: very much improved, to 7: very much worse, CGI-I responder are defined as being rated as 'unchanged', 'minimally improved', 'much improved', or 'very much improved', CGI-I non-responder are defined as being rated 'minimally worse', 'much worse' or 'very much worse'

    Time frame: Week 9

  6. Patient Global Impression - Improvement (PGI-I), FAS (LOCF)

    Patient Global Impression - Improvement on FAS, PGI-I was rated from 1: very much better, to 7: very much worse, PGI-I responder are defined as being rated as 'unchanged', 'minimally better', 'much better', or 'very much better', PGI-I non-responder are defined as being rated as 'minimally worse', 'much worse', or 'very much worse'

    Time frame: Week 9

  7. Pramipexole Dose Adaptation, FAS (LOCF)

    Patients with increase in daily Pramipexole dose on FAS

    Time frame: Week 9

  8. Final Pramipexole Dose (mg) After 9 Weeks, Treated Set

    The mean final daily Pramipexole dose is displayed

    Time frame: Week 9

07

Results

Posted Nov 20, 2009
Limitations and caveats
There were no serious adverse events in the trial and no non-serious adverse events with an incidence \>5%.

Participant flow

Participant flow — Overall Study
MilestonePramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
Started10452
Completed10049
Not completed43
Withdrew: Adverse event11
Withdrew: Withdrawal by subject22
Withdrew: Protocol violation10

Outcome measures

PrimaryPercentage of Patients Who Successfully Switched From Pramipexole Immediate Release (IR) to Pramipexole ER After a Possible Dose Adaptation, Full Analysis Set (FAS), Last Observation Carried Forward (LOCF)

A successful switch was defined by no change of the Unified Parkinson's Disease Rating Scale (UPDRS) II+III by more than 15% from baseline to week 9, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment)

Time frame:
from baseline to week 9
Reported as:
Number · Percentage of participants
Percentage of Patients Who Successfully Switched From Pramipexole Immediate Release (IR) to Pramipexole ER After a Possible Dose Adaptation, Full Analysis Set (FAS), Last Observation Carried Forward (LOCF)
Percentage of participantsPramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
Successfully switched84.594.2
Not successfully switched15.55.8
SecondaryPercentage of Patients Who Successfully Switched From Pramipexole IR to Pramipexole ER With no Dose Adaptation, FAS (LOCF)

A successful switch was defined by no change of the UPDRS II+III by more than 15% from baseline to week 4, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment).

Time frame:
from baseline to week 4
Reported as:
Number · Percentage of participants
Percentage of Patients Who Successfully Switched From Pramipexole IR to Pramipexole ER With no Dose Adaptation, FAS (LOCF)
Percentage of participantsPramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
Successfully switched81.692.3
Not successfully switched18.47.7
Statistical analysis
  • Pramipexole Extended Release (ER) vs Pramipexole Immediate Release (IR) · Wilson score interval · Risk difference (rd): -10.75 · 95% CI -20.51 to 1.48
  • Pramipexole Extended Release (ER) vs Pramipexole Immediate Release (IR) · Cochran-Mantel-Haenszel · p = 0.0803test with stratification by country
SecondaryChange From Baseline in UPDRS Part II+III Total Score at Week 9, FAS (LOCF)

Unified Parkinson's Disease Rating Scale part II+III total score on FAS, Week 9 - baseline, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment)

Time frame:
Baseline and week 9
Reported as:
Least squares mean · Score on scale
Change From Baseline in UPDRS Part II+III Total Score at Week 9, FAS (LOCF)
Score on scalePramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
Change From Baseline in UPDRS Part II+III Total Score at Week 9, FAS (LOCF)-1.6 ± 0.5-0.5 ± 0.7
Statistical analysis
  • Pramipexole Extended Release (ER) vs Pramipexole Immediate Release (IR) · ANCOVA · p = 0.2061 · Mean difference (final values): -1.1 · 95% CI -2.8 to 0.6ANCOVA with factors of treatment, country and baseline as covariate
SecondaryChange From Baseline in UPDRS Part II Total Score at Week 9, FAS (LOCF)

Unified Parkinson's Disease Rating Scale part II total score on FAS, Week 9 - baseline, UPDRS II score ranging from 0 (no impairment) to 52 (worst impairment)

Time frame:
Baseline and week 9
Reported as:
Mean · Score on Scale
Change From Baseline in UPDRS Part II Total Score at Week 9, FAS (LOCF)
Score on ScalePramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
Change From Baseline in UPDRS Part II Total Score at Week 9, FAS (LOCF)-0.3 ± 0.2-0.1 ± 0.3
Statistical analysis
  • Pramipexole Extended Release (ER) vs Pramipexole Immediate Release (IR) · ANCOVA · p = 0.4694 · Mean difference (final values): -0.2 · 95% CI -0.8 to 0.4ANCOVA with factors of treatment, country and baseline as covariate
SecondaryChange From Baseline in UPDRS Part III Total Score at Week 9, FAS (LOCF)

Unified Parkinson's Disease Rating Scale part III total score on FAS, week 9 - baseline, UPDRS II+III score ranging from 0 (no impairment) to 108 (worst impairment)

Time frame:
Baseline and week 9
Reported as:
Least squares mean · Score on Scale
Change From Baseline in UPDRS Part III Total Score at Week 9, FAS (LOCF)
Score on ScalePramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
Change From Baseline in UPDRS Part III Total Score at Week 9, FAS (LOCF)-1.2 ± 0.4-0.3 ± 0.6
Statistical analysis
  • Pramipexole Extended Release (ER) vs Pramipexole Immediate Release (IR) · ANCOVA · p = 0.1804 · Mean difference (final values): -0.9 · 95% CI -2.3 to 0.4ANCOVA with factors of treatment, country and baseline as covariate
SecondaryClinical Global Impression - Improvement (CGI-I), FAS (LOCF)

Clinical Global Impression - Improvement on FAS, CGI-I was rated from 1: very much improved, to 7: very much worse, CGI-I responder are defined as being rated as 'unchanged', 'minimally improved', 'much improved', or 'very much improved', CGI-I non-responder are defined as being rated 'minimally worse', 'much worse' or 'very much worse'

Time frame:
Week 9
Reported as:
Number · participants
Clinical Global Impression - Improvement (CGI-I), FAS (LOCF)
participantsPramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
CGI-I responder9041
CGI-I non-responder1311
Statistical analysis
  • Pramipexole Extended Release (ER) vs Pramipexole Immediate Release (IR) · Cochran-Mantel-Haenszel · p = 0.1623test with stratification by country
SecondaryPatient Global Impression - Improvement (PGI-I), FAS (LOCF)

Patient Global Impression - Improvement on FAS, PGI-I was rated from 1: very much better, to 7: very much worse, PGI-I responder are defined as being rated as 'unchanged', 'minimally better', 'much better', or 'very much better', PGI-I non-responder are defined as being rated as 'minimally worse', 'much worse', or 'very much worse'

Time frame:
Week 9
Reported as:
Number · participants
Patient Global Impression - Improvement (PGI-I), FAS (LOCF)
participantsPramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
PGI-I responder (unchanged to very much better)8437
PGI-I non-responder1915
Statistical analysis
  • Pramipexole Extended Release (ER) vs Pramipexole Immediate Release (IR) · Cochran-Mantel-Haenszel · p = 0.1299test with stratification by country
SecondaryPramipexole Dose Adaptation, FAS (LOCF)

Patients with increase in daily Pramipexole dose on FAS

Time frame:
Week 9
Reported as:
Number · participants
Pramipexole Dose Adaptation, FAS (LOCF)
participantsPramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
Daily dose increased177
Daily dose not increased8645
Statistical analysis
  • Pramipexole Extended Release (ER) vs Pramipexole Immediate Release (IR) · Cochran-Mantel-Haenszel · p = 0.6190test with stratification by country
SecondaryFinal Pramipexole Dose (mg) After 9 Weeks, Treated Set

The mean final daily Pramipexole dose is displayed

Time frame:
Week 9
Reported as:
Mean · mg
Final Pramipexole Dose (mg) After 9 Weeks, Treated Set
mgPramipexole Extended Release (ER)Pramipexole Immediate Release (IR)
Final Pramipexole Dose (mg) After 9 Weeks, Treated Set2.75 ± 0.952.83 ± 0.86

Adverse events

Collected over 9 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole Extended Release (ER)—0/104 (0%)0/104 (0%)
Pramipexole Immediate Release (IR)—0/52 (0%)0/52 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pramipexole Extended Release (ER)Pramipexole Immediate Release (IR)Total
Mean63.8 ± 8.863.5 ± 9.763.7 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Pramipexole Extended Release (ER)Pramipexole Immediate Release (IR)Total
Female472168
Male573188
08

Study locations

36 sites
  • 248.636.3303A Boehringer Ingelheim Investigational Site
    Aix en Provence, France
  • 248.636.3303B Boehringer Ingelheim Investigational Site
    Aix en Provence, France
  • 248.636.3303C Boehringer Ingelheim Investigational Site
    Aix en Provence, France
  • 248.636.3307C Boehringer Ingelheim Investigational Site
    Bron cedex, France
  • 248.636.3309B Boehringer Ingelheim Investigational Site
    Clermont Ferrand, France
  • 248.636.3305A Boehringer Ingelheim Investigational Site
    Créteil, France
  • 248.636.3305B Boehringer Ingelheim Investigational Site
    Créteil, France
  • 248.636.3313A Boehringer Ingelheim Investigational Site
    Dijon cedex, France
  • 248.636.3304A Boehringer Ingelheim Investigational Site
    Evreux, France
  • 248.636.3308B Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.636.3308C Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.636.3308D Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.636.3308E Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.636.3302A Boehringer Ingelheim Investigational Site
    Marseille cedex 5, France
  • 248.636.3302B Boehringer Ingelheim Investigational Site
    Marseille cedex 5, France
  • 248.636.3306B Boehringer Ingelheim Investigational Site
    Montpellier, France
  • 248.636.3312A Boehringer Ingelheim Investigational Site
    Rouen, France
  • 248.636.3312B Boehringer Ingelheim Investigational Site
    Rouen, France
  • 248.636.3311A Boehringer Ingelheim Investigational Site
    Strasbourg, France
  • 248.636.3301A Boehringer Ingelheim Investigational Site
    Toulouse cedex, France
  • 248.636.3301B Boehringer Ingelheim Investigational Site
    Toulouse cedex, France
  • 248.636.3301D Boehringer Ingelheim Investigational Site
    Toulouse cedex, France
  • 248.636.49006 Boehringer Ingelheim Investigational Site
    Achim bei Bremen, Germany
  • 248.636.49003 Boehringer Ingelheim Investigational Site
    Berlin-Steglitz, Germany
  • 248.636.49004 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.636.49007 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.636.49008 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.636.49002 Boehringer Ingelheim Investigational Site
    Gera, Germany
  • 248.636.49001 Boehringer Ingelheim Investigational Site
    Karlsruhe, Germany
  • 248.636.49005 Boehringer Ingelheim Investigational Site
    Unterhaching, Germany
  • 248.636.31005 Boehringer Ingelheim Investigational Site
    's-hertogenbosch, Netherlands
  • 248.636.31002 Boehringer Ingelheim Investigational Site
    Geldrop, Netherlands
  • 248.636.31003 Boehringer Ingelheim Investigational Site
    Helmond, Netherlands
  • 248.636.31006 Boehringer Ingelheim Investigational Site
    Maastricht, Netherlands
  • 248.636.31004 Boehringer Ingelheim Investigational Site
    Nijmegen, Netherlands
  • 248.636.31001 Boehringer Ingelheim Investigational Site
    Sittard, Netherlands
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007 and a primary completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2007
First posted
Nov 14, 2007
Start
Oct 2007
Primary completionActual
May 2008
Results first posted
Nov 20, 2009
Last update
May 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00558025
Responsible party
Sponsor
First posted
Nov 14, 2007
Start date
Oct 2007
Primary completion
May 2008
Results posted
Nov 20, 2009
Last update
May 16, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion